#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=The gut microbiota is an ecological community constituted by a large number of bacteria , archaea , protists , fungi and viruses .
2-1	16-19	The	abstract[3]	new[3]	coref	2-5[4_3]
2-2	20-23	gut	abstract|abstract[3]	new|new[3]	coref	4-10
2-3	24-34	microbiota	abstract[3]	new[3]	_	_
2-4	35-37	is	_	_	_	_
2-5	38-40	an	abstract[4]	giv[4]	coref	3-1[11_4]
2-6	41-51	ecological	abstract[4]	giv[4]	_	_
2-7	52-61	community	abstract[4]	giv[4]	_	_
2-8	62-73	constituted	_	_	_	_
2-9	74-76	by	_	_	_	_
2-10	77-78	a	abstract[5]	new[5]	_	_
2-11	79-84	large	abstract[5]	new[5]	_	_
2-12	85-91	number	abstract[5]	new[5]	_	_
2-13	92-94	of	abstract[5]	new[5]	_	_
2-14	95-103	bacteria	abstract[5]|animal	new[5]|new	coref	8-14[44_0]
2-15	104-105	,	abstract[5]	new[5]	_	_
2-16	106-113	archaea	abstract[5]|animal	new[5]|new	_	_
2-17	114-115	,	abstract[5]	new[5]	_	_
2-18	116-124	protists	abstract[5]|person	new[5]|new	_	_
2-19	125-126	,	abstract[5]	new[5]	_	_
2-20	127-132	fungi	abstract[5]|object	new[5]|new	_	_
2-21	133-136	and	abstract[5]	new[5]	_	_
2-22	137-144	viruses	abstract[5]|object	new[5]|new	_	_
2-23	145-146	.	_	_	_	_

#Text=The microbiota produces multiple metabolites that may cross the intestinal barrier and exert biological effects .
3-1	147-150	The	abstract[11]	giv[11]	coref	4-1[16_11]
3-2	151-161	microbiota	abstract[11]	giv[11]	_	_
3-3	162-170	produces	_	_	_	_
3-4	171-179	multiple	object[12]	new[12]	_	_
3-5	180-191	metabolites	object[12]	new[12]	_	_
3-6	192-196	that	_	_	_	_
3-7	197-200	may	_	_	_	_
3-8	201-206	cross	_	_	_	_
3-9	207-210	the	object[14]	new[14]	coref	4-9[19_14]
3-10	211-221	intestinal	abstract|object[14]	new|new[14]	_	_
3-11	222-229	barrier	object[14]	new[14]	_	_
3-12	230-233	and	_	_	_	_
3-13	234-239	exert	_	_	_	_
3-14	240-250	biological	abstract[15]	new[15]	coref	18-16[149_15]
3-15	251-258	effects	abstract[15]	new[15]	_	_
3-16	259-260	.	_	_	_	_

#Text=The microbiota also impacts on the integrity of the gut barrier .
4-1	261-264	The	abstract[16]	giv[16]	coref	6-8[31_16]
4-2	265-275	microbiota	abstract[16]	giv[16]	_	_
4-3	276-280	also	_	_	_	_
4-4	281-288	impacts	_	_	_	_
4-5	289-291	on	_	_	_	_
4-6	292-295	the	abstract[17]	new[17]	_	_
4-7	296-305	integrity	abstract[17]	new[17]	_	_
4-8	306-308	of	abstract[17]	new[17]	_	_
4-9	309-312	the	abstract[17]|object[19]	new[17]|giv[19]	coref	5-2[0_19]
4-10	313-316	gut	abstract[17]|abstract|object[19]	new[17]|giv|giv[19]	coref	9-35
4-11	317-324	barrier	abstract[17]|object[19]	new[17]|giv[19]	_	_
4-12	325-326	.	_	_	_	_

#Text=Gut barrier dysfunction may result in bacterial translocation from the intestines with increased plasma lipopolysaccharides ( LPS ) .
5-1	327-330	Gut	person|abstract[22]	new|new[22]	coref	7-1
5-2	331-338	barrier	object|abstract[22]	giv|new[22]	_	_
5-3	339-350	dysfunction	abstract[22]	new[22]	_	_
5-4	351-354	may	_	_	_	_
5-5	355-361	result	_	_	_	_
5-6	362-364	in	_	_	_	_
5-7	365-374	bacterial	substance|abstract[24]	new|new[24]	_	_
5-8	375-388	translocation	abstract[24]	new[24]	_	_
5-9	389-393	from	_	_	_	_
5-10	394-397	the	place[25]	new[25]	_	_
5-11	398-408	intestines	place[25]	new[25]	_	_
5-12	409-413	with	place[25]	new[25]	_	_
5-13	414-423	increased	place[25]|substance[27]	new[25]|new[27]	_	_
5-14	424-430	plasma	place[25]|abstract|substance[27]	new[25]|new|new[27]	_	_
5-15	431-450	lipopolysaccharides	place[25]|substance[27]	new[25]|new[27]	_	_
5-16	451-452	(	_	_	_	_
5-17	453-456	LPS	object	new	_	_
5-18	457-458	)	_	_	_	_
5-19	459-460	.	_	_	_	_

#Text=Multiple studies have found a relationship between the microbiota and adequate metabolic , hormonal and immunologic homeostasis .
6-1	461-469	Multiple	event[29]	new[29]	_	_
6-2	470-477	studies	event[29]	new[29]	_	_
6-3	478-482	have	_	_	_	_
6-4	483-488	found	_	_	_	_
6-5	489-490	a	abstract[30]	new[30]	_	_
6-6	491-503	relationship	abstract[30]	new[30]	_	_
6-7	504-511	between	abstract[30]	new[30]	_	_
6-8	512-515	the	abstract[30]|abstract[31]	new[30]|giv[31]	coref	7-11[37_31]
6-9	516-526	microbiota	abstract[30]|abstract[31]	new[30]|giv[31]	_	_
6-10	527-530	and	abstract[30]	new[30]	_	_
6-11	531-539	adequate	abstract[30]|abstract[32]	new[30]|new[32]	coref	9-1[49_32]
6-12	540-549	metabolic	abstract[30]|abstract[32]	new[30]|new[32]	_	_
6-13	550-551	,	abstract[30]	new[30]	_	_
6-14	552-560	hormonal	abstract[30]|abstract[33]	new[30]|new[33]	coref	14-10[117_33]
6-15	561-564	and	abstract[30]|abstract[33]	new[30]|new[33]	_	_
6-16	565-576	immunologic	abstract[30]|abstract[33]	new[30]|new[33]	_	_
6-17	577-588	homeostasis	abstract[30]|abstract[33]	new[30]|new[33]	_	_
6-18	589-590	.	_	_	_	_

#Text=Gut dysbiosis , i. e. , an altered composition of the intestinal microbiota in disease is associated with poor health outcomes .
7-1	591-594	Gut	person|abstract[35]	giv|new[35]	coref	8-1[0_35]
7-2	595-604	dysbiosis	abstract[35]	new[35]	_	_
7-3	605-606	,	_	_	_	_
7-4	607-609	i.	_	_	_	_
7-5	610-612	e.	_	_	_	_
7-6	613-614	,	_	_	_	_
7-7	615-617	an	abstract[36]	new[36]	_	_
7-8	618-625	altered	abstract[36]	new[36]	_	_
7-9	626-637	composition	abstract[36]	new[36]	_	_
7-10	638-640	of	abstract[36]	new[36]	_	_
7-11	641-644	the	abstract[36]|abstract[37]	new[36]|giv[37]	coref	8-24[48_37]
7-12	645-655	intestinal	abstract[36]|abstract[37]	new[36]|giv[37]	_	_
7-13	656-666	microbiota	abstract[36]|abstract[37]	new[36]|giv[37]	_	_
7-14	667-669	in	abstract[36]|abstract[37]	new[36]|giv[37]	_	_
7-15	670-677	disease	abstract[36]|abstract[37]|abstract	new[36]|giv[37]|new	_	_
7-16	678-680	is	_	_	_	_
7-17	681-691	associated	_	_	_	_
7-18	692-696	with	_	_	_	_
7-19	697-701	poor	abstract[40]	new[40]	_	_
7-20	702-708	health	abstract|abstract[40]	new|new[40]	_	_
7-21	709-717	outcomes	abstract[40]	new[40]	_	_
7-22	718-719	.	_	_	_	_

#Text=Dysbiosis may be treated with probiotics , i. e. , live strains of selected bacteria , or prebiotics , food components that modulate the microbiota .
8-1	720-729	Dysbiosis	abstract	giv	coref	10-1
8-2	730-733	may	_	_	_	_
8-3	734-736	be	_	_	_	_
8-4	737-744	treated	_	_	_	_
8-5	745-749	with	_	_	_	_
8-6	750-760	probiotics	substance	new	_	_
8-7	761-762	,	_	_	_	_
8-8	763-765	i.	_	_	_	_
8-9	766-768	e.	_	_	_	_
8-10	769-770	,	_	_	_	_
8-11	771-775	live	abstract[43]	new[43]	_	_
8-12	776-783	strains	abstract[43]	new[43]	_	_
8-13	784-786	of	abstract[43]	new[43]	_	_
8-14	787-795	selected	abstract[43]|animal[44]	new[43]|giv[44]	coref	10-51[78_44]
8-15	796-804	bacteria	abstract[43]|animal[44]	new[43]|giv[44]	_	_
8-16	805-806	,	_	_	_	_
8-17	807-809	or	_	_	_	_
8-18	810-820	prebiotics	substance	new	_	_
8-19	821-822	,	_	_	_	_
8-20	823-827	food	object|substance[47]	new|new[47]	_	_
8-21	828-838	components	substance[47]	new[47]	_	_
8-22	839-843	that	_	_	_	_
8-23	844-852	modulate	_	_	_	_
8-24	853-856	the	abstract[48]	giv[48]	coref	9-34[64_48]
8-25	857-867	microbiota	abstract[48]	giv[48]	_	_
8-26	868-869	.	_	_	_	_

#Text=Multiple metabolic , cardiovascular , and respiratory diseases including type 2 diabetes mellitus , obesity , systemic and pulmonary hypertension , atherosclerosis , heart failure and chronic respiratory diseases have been linked to impaired gut microbiota .
9-1	870-878	Multiple	abstract[49]	giv[49]	_	_
9-2	879-888	metabolic	abstract[49]	giv[49]	_	_
9-3	889-890	,	_	_	_	_
9-4	891-905	cardiovascular	abstract	new	_	_
9-5	906-907	,	_	_	_	_
9-6	908-911	and	_	_	_	_
9-7	912-923	respiratory	abstract[51]	new[51]	_	_
9-8	924-932	diseases	abstract[51]	new[51]	_	_
9-9	933-942	including	abstract[51]	new[51]	_	_
9-10	943-947	type	abstract[51]|abstract	new[51]|new	_	_
9-11	948-949	2	abstract[54]	new[54]	_	_
9-12	950-958	diabetes	abstract|abstract[54]	new|new[54]	_	_
9-13	959-967	mellitus	abstract[54]	new[54]	_	_
9-14	968-969	,	_	_	_	_
9-15	970-977	obesity	abstract	new	_	_
9-16	978-979	,	_	_	_	_
9-17	980-988	systemic	_	_	_	_
9-18	989-992	and	_	_	_	_
9-19	993-1002	pulmonary	person	new	_	_
9-20	1003-1015	hypertension	abstract	new	_	_
9-21	1016-1017	,	_	_	_	_
9-22	1018-1033	atherosclerosis	abstract	new	_	_
9-23	1034-1035	,	_	_	_	_
9-24	1036-1041	heart	object|abstract[60]	new|new[60]	_	_
9-25	1042-1049	failure	abstract[60]	new[60]	_	_
9-26	1050-1053	and	_	_	_	_
9-27	1054-1061	chronic	abstract[62]	new[62]	coref	15-15[131_62]
9-28	1062-1073	respiratory	object|abstract[62]	new|new[62]	coref	15-13
9-29	1074-1082	diseases	abstract[62]	new[62]	_	_
9-30	1083-1087	have	_	_	_	_
9-31	1088-1092	been	_	_	_	_
9-32	1093-1099	linked	_	_	_	_
9-33	1100-1102	to	_	_	_	_
9-34	1103-1111	impaired	abstract[64]	giv[64]	coref	19-12[158_64]
9-35	1112-1115	gut	abstract|abstract[64]	giv|giv[64]	coref	19-13
9-36	1116-1126	microbiota	abstract[64]	giv[64]	_	_
9-37	1127-1128	.	_	_	_	_

#Text=Dysbiosis is frequently characterized by : ( a ) lower microbial diversity and richness , ( b ) changes in the relative abundance of phyla with an increased Firmicutes to Bacteroidetes ratio ( F/B ) , and ( c ) changes in short chain fatty acids ( SCFA ) producing bacteria with a relative increase in lactate-producing bacteria and a relative decrease in acetate- and butyrate-producing bacteria .
10-1	1129-1138	Dysbiosis	event	giv	_	_
10-2	1139-1141	is	_	_	_	_
10-3	1142-1152	frequently	_	_	_	_
10-4	1153-1166	characterized	_	_	_	_
10-5	1167-1169	by	_	_	_	_
10-6	1170-1171	:	_	_	_	_
10-7	1172-1173	(	abstract[66]	new[66]	_	_
10-8	1174-1175	a	abstract[66]	new[66]	_	_
10-9	1176-1177	)	abstract[66]	new[66]	_	_
10-10	1178-1183	lower	abstract[66]	new[66]	_	_
10-11	1184-1193	microbial	abstract[66]	new[66]	_	_
10-12	1194-1203	diversity	abstract[66]	new[66]	_	_
10-13	1204-1207	and	_	_	_	_
10-14	1208-1216	richness	abstract	new	_	_
10-15	1217-1218	,	_	_	_	_
10-16	1219-1220	(	_	_	_	_
10-17	1221-1222	b	place	new	_	_
10-18	1223-1224	)	_	_	_	_
10-19	1225-1232	changes	_	_	_	_
10-20	1233-1235	in	_	_	_	_
10-21	1236-1239	the	abstract[69]	new[69]	_	_
10-22	1240-1248	relative	abstract[69]	new[69]	_	_
10-23	1249-1258	abundance	abstract[69]	new[69]	_	_
10-24	1259-1261	of	abstract[69]	new[69]	_	_
10-25	1262-1267	phyla	abstract[69]|abstract	new[69]|new	_	_
10-26	1268-1272	with	abstract[69]	new[69]	_	_
10-27	1273-1275	an	abstract[69]|abstract[71]	new[69]|new[71]	_	_
10-28	1276-1285	increased	abstract[69]|abstract[71]	new[69]|new[71]	_	_
10-29	1286-1296	Firmicutes	abstract[69]|abstract[71]	new[69]|new[71]	_	_
10-30	1297-1299	to	abstract[69]|abstract[71]	new[69]|new[71]	_	_
10-31	1300-1313	Bacteroidetes	abstract[69]|abstract[71]|person|abstract[73]	new[69]|new[71]|new|new[73]	appos	10-34[0_73]
10-32	1314-1319	ratio	abstract[69]|abstract[71]|abstract[73]	new[69]|new[71]|new[73]	_	_
10-33	1320-1321	(	_	_	_	_
10-34	1322-1325	F/B	abstract	giv	_	_
10-35	1326-1327	)	_	_	_	_
10-36	1328-1329	,	_	_	_	_
10-37	1330-1333	and	_	_	_	_
10-38	1334-1335	(	_	_	_	_
10-39	1336-1337	c	abstract	new	_	_
10-40	1338-1339	)	_	_	_	_
10-41	1340-1347	changes	_	_	_	_
10-42	1348-1350	in	_	_	_	_
10-43	1351-1356	short	abstract[76]	new[76]	appos	10-48[0_76]
10-44	1357-1362	chain	abstract[76]	new[76]	_	_
10-45	1363-1368	fatty	abstract[76]	new[76]	_	_
10-46	1369-1374	acids	abstract[76]	new[76]	_	_
10-47	1375-1376	(	_	_	_	_
10-48	1377-1381	SCFA	abstract	giv	_	_
10-49	1382-1383	)	_	_	_	_
10-50	1384-1393	producing	_	_	_	_
10-51	1394-1402	bacteria	animal[78]	giv[78]	_	_
10-52	1403-1407	with	animal[78]	giv[78]	_	_
10-53	1408-1409	a	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-54	1410-1418	relative	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-55	1419-1427	increase	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-56	1428-1430	in	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-57	1431-1448	lactate-producing	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-58	1449-1457	bacteria	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-59	1458-1461	and	animal[78]|abstract[79]	giv[78]|new[79]	_	_
10-60	1462-1463	a	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-61	1464-1472	relative	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-62	1473-1481	decrease	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-63	1482-1484	in	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-64	1485-1493	acetate-	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-65	1494-1497	and	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-66	1498-1516	butyrate-producing	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-67	1517-1525	bacteria	animal[78]|abstract[79]|event[80]	giv[78]|new[79]|new[80]	_	_
10-68	1526-1527	.	_	_	_	_

#Text=Vitamin D is produced from dermal exposure to sunlight or from the diet and is converted in the liver into 25-OH-cholecaciferol or calcifediol ( 25OHVitD ) , whose measure serves as an indicator of the vitamin D status .
11-1	1528-1535	Vitamin	substance	new	coref	11-36
11-2	1536-1537	D	person	new	coref	11-37
11-3	1538-1540	is	_	_	_	_
11-4	1541-1549	produced	_	_	_	_
11-5	1550-1554	from	_	_	_	_
11-6	1555-1561	dermal	animal|abstract[84]	new|new[84]	coref	13-17[111_84]
11-7	1562-1570	exposure	abstract[84]	new[84]	_	_
11-8	1571-1573	to	abstract[84]	new[84]	_	_
11-9	1574-1582	sunlight	abstract[84]|substance	new[84]|new	_	_
11-10	1583-1585	or	_	_	_	_
11-11	1586-1590	from	_	_	_	_
11-12	1591-1594	the	substance[86]	new[86]	_	_
11-13	1595-1599	diet	substance[86]	new[86]	_	_
11-14	1600-1603	and	_	_	_	_
11-15	1604-1606	is	_	_	_	_
11-16	1607-1616	converted	_	_	_	_
11-17	1617-1619	in	_	_	_	_
11-18	1620-1623	the	object[87]	new[87]	_	_
11-19	1624-1629	liver	object[87]	new[87]	_	_
11-20	1630-1634	into	object[87]	new[87]	_	_
11-21	1635-1655	25-OH-cholecaciferol	object[87]|quantity	new[87]|new	_	_
11-22	1656-1658	or	object[87]	new[87]	_	_
11-23	1659-1670	calcifediol	object[87]	new[87]	_	_
11-24	1671-1672	(	object[87]	new[87]	_	_
11-25	1673-1681	25OHVitD	object[87]|quantity	new[87]|new	_	_
11-26	1682-1683	)	object[87]	new[87]	_	_
11-27	1684-1685	,	_	_	_	_
11-28	1686-1691	whose	abstract[90]	new[90]	_	_
11-29	1692-1699	measure	abstract[90]	new[90]	_	_
11-30	1700-1706	serves	_	_	_	_
11-31	1707-1709	as	_	_	_	_
11-32	1710-1712	an	_	_	_	_
11-33	1713-1722	indicator	_	_	_	_
11-34	1723-1725	of	_	_	_	_
11-35	1726-1729	the	abstract[93]	new[93]	_	_
11-36	1730-1737	vitamin	substance|abstract[93]	giv|new[93]	ana	12-1
11-37	1738-1739	D	person|abstract[93]	giv|new[93]	coref	12-25
11-38	1740-1746	status	abstract[93]	new[93]	_	_
11-39	1747-1748	.	_	_	_	_

#Text=This is further metabolized mainly in the kidney into 1-α,25-dihydroxycholecalciferol , the most active form , also named calcitriol , which activates the vitamin D receptor ( VDR ) .
12-1	1749-1753	This	substance	giv	coref	12-24
12-2	1754-1756	is	_	_	_	_
12-3	1757-1764	further	_	_	_	_
12-4	1765-1776	metabolized	_	_	_	_
12-5	1777-1783	mainly	_	_	_	_
12-6	1784-1786	in	_	_	_	_
12-7	1787-1790	the	place[95]	new[95]	_	_
12-8	1791-1797	kidney	place[95]	new[95]	_	_
12-9	1798-1802	into	_	_	_	_
12-10	1803-1834	1-α,25-dihydroxycholecalciferol	quantity	new	_	_
12-11	1835-1836	,	_	_	_	_
12-12	1837-1840	the	substance[97]	new[97]	_	_
12-13	1841-1845	most	substance[97]	new[97]	_	_
12-14	1846-1852	active	substance[97]	new[97]	_	_
12-15	1853-1857	form	substance[97]	new[97]	_	_
12-16	1858-1859	,	_	_	_	_
12-17	1860-1864	also	_	_	_	_
12-18	1865-1870	named	_	_	_	_
12-19	1871-1881	calcitriol	substance	new	coref	16-9
12-20	1882-1883	,	_	_	_	_
12-21	1884-1889	which	_	_	_	_
12-22	1890-1899	activates	_	_	_	_
12-23	1900-1903	the	substance[101]	new[101]	_	_
12-24	1904-1911	vitamin	substance|substance[101]	giv|new[101]	coref	13-1
12-25	1912-1913	D	person|substance[101]	giv|new[101]	coref	13-2
12-26	1914-1922	receptor	substance[101]	new[101]	_	_
12-27	1923-1924	(	_	_	_	_
12-28	1925-1928	VDR	abstract	new	coref	16-12
12-29	1929-1930	)	_	_	_	_
12-30	1931-1932	.	_	_	_	_

#Text=Vitamin D deficiency , which causes rickets and osteomalacia , is very common worldwide due to insufficient solar light exposure and/or a reduced dietary intake .
13-1	1933-1940	Vitamin	substance|abstract[105]	giv|new[105]	coref|coref	13-12[108_105]|14-13
13-2	1941-1942	D	person|abstract[105]	giv|new[105]	coref	14-13[119_0]
13-3	1943-1953	deficiency	abstract[105]	new[105]	_	_
13-4	1954-1955	,	_	_	_	_
13-5	1956-1961	which	_	_	_	_
13-6	1962-1968	causes	_	_	_	_
13-7	1969-1976	rickets	abstract	new	_	_
13-8	1977-1980	and	_	_	_	_
13-9	1981-1993	osteomalacia	abstract	new	_	_
13-10	1994-1995	,	_	_	_	_
13-11	1996-1998	is	_	_	_	_
13-12	1999-2003	very	abstract[108]	giv[108]	coref	15-1[127_108]
13-13	2004-2010	common	abstract[108]	giv[108]	_	_
13-14	2011-2020	worldwide	abstract[108]	giv[108]	_	_
13-15	2021-2024	due	abstract[108]	giv[108]	_	_
13-16	2025-2027	to	_	_	_	_
13-17	2028-2040	insufficient	abstract[111]	giv[111]	_	_
13-18	2041-2046	solar	person|abstract[111]	new|giv[111]	_	_
13-19	2047-2052	light	abstract|abstract[111]	new|giv[111]	_	_
13-20	2053-2061	exposure	abstract[111]	giv[111]	_	_
13-21	2062-2068	and/or	abstract[111]	giv[111]	_	_
13-22	2069-2070	a	abstract[111]|event[113]	giv[111]|new[113]	_	_
13-23	2071-2078	reduced	abstract[111]|event[113]	giv[111]|new[113]	_	_
13-24	2079-2086	dietary	abstract[111]|abstract|event[113]	giv[111]|new|new[113]	_	_
13-25	2087-2093	intake	abstract[111]|event[113]	giv[111]|new[113]	_	_
13-26	2094-2095	.	_	_	_	_

#Text=Besides this well-known regulatory role in the calcium-phosphorus and bone homeostasis , vitamin D is also involved in the control of other physiological processes , such as cellular growth , intracellular metabolism and innate and adaptive immunity .
14-1	2096-2103	Besides	_	_	_	_
14-2	2104-2108	this	abstract[114]	new[114]	_	_
14-3	2109-2119	well-known	abstract[114]	new[114]	_	_
14-4	2120-2130	regulatory	abstract[114]	new[114]	_	_
14-5	2131-2135	role	abstract[114]	new[114]	_	_
14-6	2136-2138	in	abstract[114]	new[114]	_	_
14-7	2139-2142	the	abstract[114]|substance[115]	new[114]|new[115]	_	_
14-8	2143-2161	calcium-phosphorus	abstract[114]|substance[115]	new[114]|new[115]	_	_
14-9	2162-2165	and	abstract[114]	new[114]	_	_
14-10	2166-2170	bone	abstract[114]|object|abstract[117]	new[114]|new|giv[117]	_	_
14-11	2171-2182	homeostasis	abstract[114]|abstract[117]	new[114]|giv[117]	_	_
14-12	2183-2184	,	_	_	_	_
14-13	2185-2192	vitamin	substance|person[119]	giv|giv[119]	coref|coref	15-1|15-2[0_119]
14-14	2193-2194	D	person[119]	giv[119]	_	_
14-15	2195-2197	is	_	_	_	_
14-16	2198-2202	also	_	_	_	_
14-17	2203-2211	involved	_	_	_	_
14-18	2212-2214	in	_	_	_	_
14-19	2215-2218	the	abstract[120]	new[120]	_	_
14-20	2219-2226	control	abstract[120]	new[120]	_	_
14-21	2227-2229	of	abstract[120]	new[120]	_	_
14-22	2230-2235	other	abstract[120]|abstract[121]	new[120]|new[121]	_	_
14-23	2236-2249	physiological	abstract[120]|abstract[121]	new[120]|new[121]	_	_
14-24	2250-2259	processes	abstract[120]|abstract[121]	new[120]|new[121]	_	_
14-25	2260-2261	,	abstract[120]	new[120]	_	_
14-26	2262-2266	such	abstract[120]	new[120]	_	_
14-27	2267-2269	as	abstract[120]	new[120]	_	_
14-28	2270-2278	cellular	abstract[120]|abstract[122]	new[120]|new[122]	_	_
14-29	2279-2285	growth	abstract[120]|abstract[122]	new[120]|new[122]	_	_
14-30	2286-2287	,	abstract[120]	new[120]	_	_
14-31	2288-2301	intracellular	abstract[120]|abstract[123]	new[120]|new[123]	_	_
14-32	2302-2312	metabolism	abstract[120]|abstract[123]	new[120]|new[123]	_	_
14-33	2313-2316	and	abstract[120]	new[120]	_	_
14-34	2317-2323	innate	abstract[120]|abstract[124]	new[120]|new[124]	_	_
14-35	2324-2327	and	abstract[120]|abstract[124]	new[120]|new[124]	_	_
14-36	2328-2336	adaptive	abstract[120]|abstract[124]	new[120]|new[124]	_	_
14-37	2337-2345	immunity	abstract[120]|abstract[124]	new[120]|new[124]	_	_
14-38	2346-2347	.	_	_	_	_

#Text=Vitamin D deficiency has also been related to infection , cancer and respiratory and cardiovascular diseases .
15-1	2348-2355	Vitamin	substance|abstract[127]	giv|giv[127]	coref|coref	17-3|19-4[153_127]
15-2	2356-2357	D	person|abstract[127]	giv|giv[127]	coref	17-3[137_0]
15-3	2358-2368	deficiency	abstract[127]	giv[127]	_	_
15-4	2369-2372	has	_	_	_	_
15-5	2373-2377	also	_	_	_	_
15-6	2378-2382	been	_	_	_	_
15-7	2383-2390	related	_	_	_	_
15-8	2391-2393	to	_	_	_	_
15-9	2394-2403	infection	event	new	_	_
15-10	2404-2405	,	_	_	_	_
15-11	2406-2412	cancer	event	new	_	_
15-12	2413-2416	and	_	_	_	_
15-13	2417-2428	respiratory	abstract	giv	_	_
15-14	2429-2432	and	_	_	_	_
15-15	2433-2447	cardiovascular	abstract[131]	giv[131]	_	_
15-16	2448-2456	diseases	abstract[131]	giv[131]	_	_
15-17	2457-2458	.	_	_	_	_

#Text=Immune cells and peripheral tissues can also synthetize calcitriol and express VDR .
16-1	2459-2465	Immune	object[132]	new[132]	_	_
16-2	2466-2471	cells	object[132]	new[132]	_	_
16-3	2472-2475	and	_	_	_	_
16-4	2476-2486	peripheral	object[133]	new[133]	_	_
16-5	2487-2494	tissues	object[133]	new[133]	_	_
16-6	2495-2498	can	_	_	_	_
16-7	2499-2503	also	_	_	_	_
16-8	2504-2514	synthetize	_	_	_	_
16-9	2515-2525	calcitriol	substance	giv	_	_
16-10	2526-2529	and	_	_	_	_
16-11	2530-2537	express	_	_	_	_
16-12	2538-2541	VDR	abstract	giv	_	_
16-13	2542-2543	.	_	_	_	_

#Text=Thus , vitamin D has been proposed to have immunomodulatory properties and insufficient vitamin D levels may lead to dysregulation of immune responses .
17-1	2544-2548	Thus	_	_	_	_
17-2	2549-2550	,	_	_	_	_
17-3	2551-2558	vitamin	substance|person[137]	giv|giv[137]	coref|coref	17-14|17-15[0_137]
17-4	2559-2560	D	person[137]	giv[137]	_	_
17-5	2561-2564	has	_	_	_	_
17-6	2565-2569	been	_	_	_	_
17-7	2570-2578	proposed	_	_	_	_
17-8	2579-2581	to	_	_	_	_
17-9	2582-2586	have	_	_	_	_
17-10	2587-2603	immunomodulatory	abstract[138]	new[138]	_	_
17-11	2604-2614	properties	abstract[138]	new[138]	_	_
17-12	2615-2618	and	_	_	_	_
17-13	2619-2631	insufficient	abstract[141]	new[141]	_	_
17-14	2632-2639	vitamin	substance|abstract[141]	giv|new[141]	coref	18-3[145_0]
17-15	2640-2641	D	person|abstract[141]	giv|new[141]	coref	19-7[155_0]
17-16	2642-2648	levels	abstract[141]	new[141]	_	_
17-17	2649-2652	may	_	_	_	_
17-18	2653-2657	lead	_	_	_	_
17-19	2658-2660	to	_	_	_	_
17-20	2661-2674	dysregulation	event[142]	new[142]	_	_
17-21	2675-2677	of	event[142]	new[142]	_	_
17-22	2678-2684	immune	event[142]|abstract|abstract[144]	new[142]|new|new[144]	_	_
17-23	2685-2694	responses	event[142]|abstract[144]	new[142]|new[144]	_	_
17-24	2695-2696	.	_	_	_	_

#Text=Moreover , vitamin D is able to induce the expression of antibacterial proteins and exert antibiotic effects in a variety of cell types .
18-1	2697-2705	Moreover	_	_	_	_
18-2	2706-2707	,	_	_	_	_
18-3	2708-2715	vitamin	substance[145]	giv[145]	coref	19-7[0_145]
18-4	2716-2717	D	substance[145]	giv[145]	_	_
18-5	2718-2720	is	_	_	_	_
18-6	2721-2725	able	_	_	_	_
18-7	2726-2728	to	_	_	_	_
18-8	2729-2735	induce	_	_	_	_
18-9	2736-2739	the	event[146]	new[146]	_	_
18-10	2740-2750	expression	event[146]	new[146]	_	_
18-11	2751-2753	of	event[146]	new[146]	_	_
18-12	2754-2767	antibacterial	event[146]|substance[147]	new[146]|new[147]	_	_
18-13	2768-2776	proteins	event[146]|substance[147]	new[146]|new[147]	_	_
18-14	2777-2780	and	_	_	_	_
18-15	2781-2786	exert	_	_	_	_
18-16	2787-2797	antibiotic	substance|abstract[149]	new|giv[149]	_	_
18-17	2798-2805	effects	abstract[149]	giv[149]	_	_
18-18	2806-2808	in	_	_	_	_
18-19	2809-2810	a	abstract[150]	new[150]	_	_
18-20	2811-2818	variety	abstract[150]	new[150]	_	_
18-21	2819-2821	of	abstract[150]	new[150]	_	_
18-22	2822-2826	cell	abstract[150]|place[151]	new[150]|new[151]	_	_
18-23	2827-2832	types	abstract[150]|place[151]	new[150]|new[151]	_	_
18-24	2833-2834	.	_	_	_	_

#Text=We hypothesized that a deficiency in vitamin D induces changes in the gut microbiota .
19-1	2835-2837	We	person	acc	_	_
19-2	2838-2850	hypothesized	_	_	_	_
19-3	2851-2855	that	_	_	_	_
19-4	2856-2857	a	abstract[153]	giv[153]	_	_
19-5	2858-2868	deficiency	abstract[153]	giv[153]	_	_
19-6	2869-2871	in	abstract[153]	giv[153]	_	_
19-7	2872-2879	vitamin	abstract[153]|substance|substance[155]	giv[153]|giv|giv[155]	_	_
19-8	2880-2881	D	abstract[153]|substance[155]	giv[153]|giv[155]	_	_
19-9	2882-2889	induces	_	_	_	_
19-10	2890-2897	changes	abstract	new	_	_
19-11	2898-2900	in	_	_	_	_
19-12	2901-2904	the	abstract[158]	giv[158]	_	_
19-13	2905-2908	gut	abstract|abstract[158]	giv|giv[158]	_	_
19-14	2909-2919	microbiota	abstract[158]	giv[158]	_	_
19-15	2920-2921	.	_	_	_	_
